Business Context and Reporting Period
This Form 6-K filing by Sanofi, dated March 4, 2026, reports recent corporate governance events and executive compensation arrangements. The filing details the termination of Paul Hudson as Chief Executive Officer (CEO) effective February 17, 2026, and his subsequent resignation as a director on February 18, 2026. It also outlines the appointment of Olivier Charmeil as Interim CEO and the compensation policy for Belén Garijo, the future CEO, whose term is scheduled to begin following the Annual General Meeting on April 29, 2026.
Key Financial Metrics and Compensation Arrangements
The filing does not provide consolidated revenue, profit, cash flow, or debt metrics for the company. Instead, it focuses on specific executive compensation figures:
- Paul Hudson (Outgoing CEO):
- Fixed Compensation (2026): Pro-rated gross annual fixed compensation of €1,600,000 through February 17, 2026.
- Variable Compensation (2025): Gross amount of €2,616,000 (163.53% of fixed), based on a 109% global attainment rate. Payment is subject to shareholder approval.
- Equity Awards: 75,206 performance shares vested from the 2023 plan (valued at approx. €5.88M). Pro-rated rights retained for 2024 and 2025 plans (potential value approx. €5.76M if 100% attainment is met).
- Termination Benefit: Gross amount of €5,207,750, capped at 24 months of base salary plus twice the last variable compensation, reduced by the non-compete indemnity.
- Non-Compete Indemnity: €3,124,650 for a nine-month period.
- Pension Plan: 2025 top-up contribution of €527,000 (50% to fund manager, 50% to CEO for tax/social charges).
- Olivier Charmeil (Interim CEO):
- Compensation maintained at Executive Vice-President levels plus top-up compensation for the interim role, calculated pro-rata based on the previous CEO's policy (€1.6M fixed target).
- Forfeits equity-based compensation and benefits in kind for the interim period.
- Belén Garijo (Future CEO):
- Fixed Compensation: €1,600,000 gross annually.
- Variable Compensation: Target 150% of fixed (range 0-250%), contingent on financial (Sales, FCF, EPS) and qualitative criteria.
- Equity-Based Compensation: Total of 360,000 shares over four years.
- Long-Term Tranche: 180,000 shares awarded at start of term; 5-year vesting; 80% weighted on Total Shareholder Return (TSR) vs. peers.
- Medium-Term Tranches: 45,000 shares annually; 3-year vesting; weighted on Business EPS (30%), FCF (20%), TSR (30%), CSR (10%), and R&D Pipeline (10%).
- Relocation Benefit: Capped at 15% of target annual compensation over four years.
- Termination Benefit: Capped at 12 months of total compensation (reduced from 24 months for the previous CEO).
Material Changes Versus Prior Period
- Leadership Transition: Paul Hudson's departure marks a significant change in executive leadership, with Olivier Charmeil serving as Interim CEO until Belén Garijo's appointment.
- Compensation Structure Shift: The new CEO policy for Belén Garijo introduces a more rigorous long-term equity structure. Unlike the previous CEO, 55% of her total equity award is linked to relative TSR performance over a longer period (5 years for the Long-Term Tranche), emphasizing sustainable value creation.
- Benefit Reductions: The future CEO is not entitled to the top-up defined-contribution pension scheme available to Paul Hudson. Additionally, the maximum termination benefit for forced departure is reduced from 24 months to 12 months of total compensation.
- Correction of Prior Data: The filing corrects an error in the 2025 Form 20-F regarding Paul Hudson's 2025 variable remuneration achievement rate, clarifying it as 109% rather than 100%.
Guidance, Outlook, and Risks
Management Commentary and Strategy: The Board emphasizes a strategic focus on strengthening the R&D pipeline, digital transformation, and AI development. The compensation policy for the new CEO is designed to align with these priorities, specifically weighting R&D pipeline and digital transformation in performance criteria.
Risks and Contingencies:
- Shareholder Approval: Payment of Paul Hudson's 2025 variable compensation and pension contributions, as well as the cash component of Belén Garijo's relocation benefit, are contingent upon approval by the Annual General Meeting of Shareholders.
- Performance Conditions: Significant portions of executive compensation are "at-risk." For example, if Sanofi's TSR ranks lower than the median of its peer panel, the TSR allocation rate for the Long-Term Tranche is 0%.
- Clawback Policy: Sanofi has adopted a clawback policy compliant with NASDAQ Rule 5608, requiring the recovery of erroneously awarded variable compensation in the event of financial restatements.
- Non-Compete Restrictions: Both the outgoing and incoming CEOs are subject to strict non-compete clauses. Violation of these clauses results in the forfeiture of performance shares and indemnities.
Key Facts for Investor Verification
- Verify the outcome of the shareholder vote on April 29, 2026, regarding the approval of Paul Hudson's 2025 variable compensation and pension contributions.
- Confirm the official start date of Belén Garijo's term and the finalization of her equity award grant date.
- Monitor the vesting conditions for the new CEO's Long-Term Tranche, specifically the 5-year TSR performance relative to the 12-company peer panel.
- Review the 2025 Form 20-F for the corrected performance data regarding Paul Hudson's 2025 variable remuneration (109% attainment).
- Assess the impact of the reduced termination benefit cap (12 months vs. 24 months) on executive retention and risk management.